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a b s t r a c t 
Dehydroepiandrosterone (DHEA) and the dehydroepiandrosterone sulfate (DHEA-S) are steroids pro-
duced mainly by the adrenal cortex. There is evidence from both human and animal models suggest-
ing beneﬁcial effects of these steroids for obesity, diabetes mellitus, hypertension, and osteoporosis,
conditions associated with the post-menopausal period. Accordingly, we hypothesized that DHEA sup-
plementation in ovariectomized (OVX) female rats fed a high-fat diet would maintain glucose-induced
insulin secretion (GSIS) and pancreatic islet function. OVX resulted in a 30% enlargement of the pan-
creatic islets area compared to the control rats, which was accompanied by a 50% reduction in the
phosphorylation of AKT protein in the pancreatic islets. However, a short-term high-fat diet induced in-
sulin resistance, accompanied by impaired GSIS in isolated pancreatic islets. These effects were reversed
by DHEA treatment, with improved insulin sensitivity to levels similar to the control group, and with
increased serine phosphorylation of the AKT protein. These data conﬁrm the protective effect of DHEA
on the endocrine pancreas in a situation of diet-induced overweight and low estrogen concentrations,
a phenotype similar to that of the post-menopausal period. 
C © 2014 The Authors. Published by Elsevier B.V. on behalf of Federation of European Biochemical
Societies. All rights reserved.  
 
 
 
 
 
 
 
 
 
 
 
 Introduction 
Menopause coincides with an increase in body fatness and asso-
ciated comorbidities such as insulin resistance, diabetes, and cardio-
vascular disease [ 1 , 2 ], which may be explained, at least in part, by
reduced secretion of sex hormones, including estrogen [ 3 ]. Estrogen
has been shown to play a pivotal role in regulating energy expen-
diture, body weight and fat distribution in women. Both human and This is an open-access article distributed under the terms of the Creative Com- 
mons Attribution-NonCommercial-No Derivative Works License, which permits non- 
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http://dx.doi.org/10.1016/j.fob.2014.01.005 murine models provide evidence for estrogen’s protective role against
obesity and type 2 diabetes (T2D) [ 4 –6 ]. Experimental studies have
shown that estrogen and its receptors protect pancreatic islets cells
from lipotoxicity and apoptosis, as well as restores glucose-induced
insulin secretion (GSIS) [ 6 –12 ]. Furthermore, the functions of pan-
creatic β cells, including the regulation of insulin secretion, nutrient
homeostasis, and even survival can be modulated by 17 β-estradiol
[ 13 ]. 
It is suggested that there is a contribution of downstream elements
in the insulin signaling pathway for β cell function and survival. For
example, expression of multiple insulin signaling proteins is reduced
in islets of patients with T2D [ 14 , 15 ]. Several lines of evidence indicate
that activation of phosphoinositide 3-kinase (PI3K) signaling pathway
plays an important role to regulate β cell mass and function. One of
the major targets of PI3-kinase is the serine–threonine kinase Akt
[ 16 , 17 ], which acts as a convergent target of several growth signals
induced by growth factors and insulin. In fact, studies suggest that
selective modulation of the Akt signaling could have positively impact
for the design of pharmaceutical agents that induce β cell function
and proliferation without adverse effect [ 18 ]. 
Dehydroepiandrosterone (DHEA), and its sulfated form DHEA-S,
are synthesized by both adrenal and gonadal glands. These steroids
are precursor of both androgens and estrogens. In humans, circulat-
ing DHEA and DHEA-S levels are markedly decreased with aging [ 19 ].f European Biochemical Societies. All rights reserved. 
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SHEA has been considered an alternative to estrogen replacement 
herapy since it has no effects on breast and endometrium cancer de- 
elopment [ 20 ]. Although no speciﬁc receptors for DHEA or DHEA-S 
ave been identiﬁed, these steroids have been shown to have antioxi- 
ant and metabolic effects in different tissues [ 21 , 22 ]. Indeed, experi- 
ental evidence from animal models and studies on postmenopausal 
omen has shown that DHEA supplementation improves insulin sen- 
itivity and reduces fat mass gain, and obesity [ 23 –26 ]. In addition, 
n streptozotocin-induced diabetic mice, DHEA was able to preserve 
ancreatic islet cell structure, while the administration of DHEA-S 
mproved the insulin secretion [ 23 , 27 ]. 
We therefore hypothesized that DHEA supplementation in 
variectomized female rats fed a high-fat diet would maintain 
lucose-induced insulin secretion and pancreatic islet function. 
aterials and methods 
xperimental model 
Female Wistar rats (8 weeks of age, weighing 150–180 g at the be- 
inning of the experiments) were obtained from our breeding colony 
t the Institute of Biomedical Sciences. The animals were housed at 
onstant room temperature, 12 h light and 12 h darkness cycle, 60% 
umidity, fed standard rat chow [3.8 kcal / g (63% carbohydrate, 26% 
roteins, and 11% fat), NUVILAB-CR, Colombo, PR, Brazil], and water 
ade available ad libitum. The rats were anesthetized with thiopen- 
al (5 mg / 100 g, i.p.; Crist ´alia, S ˜ ao Paulo, SP, Brazil) and were sub- 
itted to sham surgery or bilateral ovariectomy (OVX). After the sur- 
ical procedure, the rats received standard chow or a high-fat diet 
HFD) [5.4 kcal / g (26% carbohydrate, 15% proteins, and 59% fat), Prag 
olu c ¸ ˜ oes Bioci ˆ encias Ltda, Jau, SP, Brazil] for the next 6 weeks. Half 
f the OVX rats fed a HFD (OHL group) was exposed to a second sur- 
ical procedure 3 weeks from the ovariectomy, which included the 
mplantation of DHEA pellet (50 mg released by 21 days) into the 
ubcutaneous back region (identiﬁed as the OHLD group). This study 
as approved by the ethical committee of the Institute of Biomedi- 
al Sciences, University of Sao Paulo (2708 / CEEA). At the end of the 
rotocol period the animals were killed with deep anesthesia, the 
ancreata were excised and the blood was used for the determina- 
ion of DHEA using an ELISA kit. In addition, estradiol (E2), proges- 
erone (P), luteinizing hormone (LH), follicle stimulating hormone 
FSH), testosterone (T) and insulin concentrations were measured by 
adioimmunoassay (RIA). 
aterials 
Reagents for SDS–PAGE and immunoblotting were obtained from 
io-Rad (Richmond, CA). Human biosynthetic DHEA, Tris, aprotinin, 
ithiotreitol, Triton X-100, glycerol, Tween 20, bovine serum albu- 
in (BSA, fraction V), propidium iodide (PI) were obtained from 
igma (St. Louis, MO). Human insulin from Lilly, American; nitro- 
ellulose (0.45 lm) and enhanced chemiluminescence kit were pur- 
hased from Pharmacia (Uppsala, Sweden). Anti-phosphoserine 473 
kt (pSer 473 Akt), anti-Akt and anti- α-Tubulin antibody were pur- 
hased from Santa Cruz Biotechnology (Santa Cruz, CA). Antibody 
gainst ERK1 / 2 was obtained from Millipore antibody (CA, USA), and 
nti-cleaved caspase 3 antibody was obtained from Cell Signaling Tech- 
ology. Biotinylated goat anti-rabbit antibody was obtained from Vec- 
or Laboratories (Burlingame, CA). Rat insulin standards and anti-rat 
nsulin antibodies were a gift from Dr. Leclercq-Meyer, Universit ´e 
ibre de Bruxelles, Belgium. 
nsulin sensitivity and glucose tolerance 
Under anesthesia (Thiopental 0.6 mg kg −1 , i.p; Crist ´alia, S ˜ ao Paulo, 
P, Brazil), 12 h fasting animals underwent a 30-min insulin tolerance test (short ITT) and a glucose tolerance test (GTT). Brieﬂy, blood glu- 
cose concentrations were measured using a glucometer (Acue check 
active Roche). The time points for the ITT were basal (0), 5, 10, 15, 
20, 25 and 30 min after the intraperitoneal insulin injection (0.75 U / 
kg). The glucose disappearance rate (Kitt) was calculated as the slope 
of linear regression of glucose concentration from 5 to 30 min af- 
ter insulin administration [ 28 ]. For GTT, the rats received 1 mg / g 
glucose through intraperitoneal injection and glucose concentrations 
was measured at the following time points: basal (0), 15, 30, 45, 60, 
90, and 120 min after the infusion. 
Morphometry of the endocrine pancreas 
The animals were deeply anesthetized with a mixture of ketamine 
(5 mg / 100 g) and xylazine (1 mg / 100 g) intramuscularly, and were 
perfused through the heart with 0.9% PBS and 4% paraformaldehyde 
in 0.1 mol / l phosphate buffer. The pancreas were excised and dis- 
sected free from surrounding tissues and ﬁxed by immersion in 4% 
formaldehyde–PBS solution for 4–6 h, followed by transfer to 30% su- 
crose PBS for cryoprotection. Frozen pancreas sections (12 μm) were 
cut on a cryostat and mounted on gelatin-coated slides. The pancreas 
sections were counter-stained with hematoxylin–eosin for morpho- 
metric analysis. The islet area was calculated by using NIH Image J 
program developed at the US National Institutes of Health and avail- 
able on http: // rsb.info.nih.gov / nih-image / . 
Pancreatic islets isolation 
The islets were isolated by collagenase digestion of the pancre- 
ata using the method described by Lacy and Kostianovsky (1967) 
[ 29 ]. Brieﬂy, the pancreas was inﬂated with a Hanks solution contain- 
ing 0.7 g / l type IV collagenase (Sigma–Aldrich Chemical, St. Louis, 
MO), excised and then maintained at 37 ◦C for about 25 min. The 
digested tissue was harvested and the islets were hand-picked. A 
Krebs–Henseleit buffer containing 115 mM NaCl, 5 mM KCl, 24 mM 
NaHCO 3 , 1 mM CaCl 2 , and 1 mM MgCl 2 was used for isolation and 
pooling of the islets. Pancreatic islets were subjected to the following 
analysis: glucose-stimulated insulin secretion (GSIS), DNA fragmen- 
tation, and typical immunoblotting. 
Glucose-stimulated insulin secretion (GSIS) assay 
Pre-incubations of 5 islets were carried out at 37 ◦C for 30 min in 
0.5 ml Krebs–Henseleit buffer and 0.2% albumin in the presence of 
5.6 mM glucose. After 5.6 mM glucose pre-incubation, the following 
concentrations of glucose were used for incubation: 2.8 and 16.7 mM 
glucose for 60 min and equilibrated with a mixture of O 2 (95%) and 
CO 2 (5%). At the end of the incubation period, insulin concentrations 
were measured by RIA [ 30 ]. 
DNA fragmentation 
DNA fragmentation was analyzed by ﬂow cytometry after DNA 
staining with PI as described previously [ 31 , 32 ]. Brieﬂy, 30 isolated 
pancreatic islets were suspended in 300 μl of hypotonic solution con- 
taining 50 mg / ml PI, 0.1% sodium citrate, and 0.1% Triton X-100, and 
incubated for 30 min at room temperature protected from light ex- 
posure. Fluorescence was measured in a FACSCalibur ﬂow cytometer 
(Becton Dickinson, Franklin Lakes, NJ) and the FL2 channel (orange / 
red ﬂuorescence at 585 / 42 nm) and analyzed using the Cell Quest 
software (Becton Dickinson). 
Immunoblotting 
Batches of 300 islets from each group were homogenized by son- 
ication (90 s) in 80 μl extraction buffer (100 mM Trizma, 1% SDS, 
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Fig. 1. Glucose tolerance test during 120 min after intraperitoneal glucose bolus. 
* Indicates that SHAM is different from SHL ( P < 0.05). # Indicates that OVX is different 
from OHL ( P < 0.05). 
Fig. 2. GSIS of isolated pancreatic islets in SHAM, SHL, OVX, OHL and OHLD groups. 
Panel A is the 60-min insulin secretion at 2.8 mM glucose (basal) and 16.7 mM glucose 
(stimulus). Panel B is the difference between the stimulus and the basal insulin secre- 
tion. Values are mean ± S.E.M., and distinct letters indicates signiﬁcant differences ( P 
< 0.05). 
 
 
 
 
 100 mM sodium pyrophosphate, 100 mM sodium ﬂuoride, 10 mM
EDTA and 10 mM sodium vanadate), and boiled for 5 min. The ex-
tracts were then centrifuged at 12,000 rpm at 4 ◦C for 20 min to re-
move insoluble material. Protein determination of the supernatants
was performed by the Bradford dye method (BioRad Laboratories,
Hercules, CA). The proteins were treated with Laemmli sample buffer
containing dithiotreitol and boiled for 5 min before loading onto 8%
SDS–PAGE in a Bio-Rad miniature slab gel apparatus. Similar sized
aliquots (30 μg) were subjected to SDS–PAGE. Electro-transfer of pro-
teins from the gel to nitrocellulose was performed for 1 h at 120 V
(constant) in a Bio-Rad miniature transfer apparatus. Non-speciﬁc
protein binding to the nitrocellulose was reduced by preincubation
for 1 h at 22 ◦C in blocking buffer containing 5% nonfat dry milk,
10 mM Tris, 150 mM NaCl, and 0.02% Tween 20. The nitrocellulose
membranes were incubated overnight at 8 ◦C with speciﬁc antibod-
ies diluted in blocking buffer added with 3% nonfat dry milk, and
then washed for 30 min in blocking buffer without milk. The blots
were subsequently incubated with peroxidase-conjugated secondary
antibody for 1 h, and processed for enhanced chemiluminescence to
visualize the immunoreactive bands. Band intensities were quantized
by optical densitometry (Scion Image-Release Beta 3b, NIH, USA) of
the developed autoradiography. 
Statistical analysis 
The results were expressed as means ± standard error (SEM). Af-
ter Gaussian distribution analysis, differences in body weights were
assessed by two-way repeated measures ANOVA (6 × 3) considering
time and group as ﬁxed factors and experimental units (female rats)
as random factor (with a Tukey–Kramer test for multiple compar-
isons). Kitt, GSIS, and pancreatic islets area were assessed by one-way
ANOVA. The alpha level of signiﬁcance was set at P < 0.05. 
Results 
Characteristics of the animals 
Circulating levels of sex hormones in the ovariectomized rats are
presented in Table 1 . Compared to sham-operated rats, ovariectomy
was associated with a 0.5-fold decrease in estradiol, a 0.3-fold de-
crease in P and T concentrations, and a concomitant 6.5-fold increase
in FSH and LH concentrations. In the ovariectomized rats, the DHEA
pellet induced an approximately 2-fold increase in the blood DHEA
levels, with a simultaneous increase in blood estradiol levels to lev-
els similar to those measured in the sham-operated rats. In contrast,
DHEA had no effect on blood LH, FSH, progesterone, and testosterone
concentrations. 
Table 2 describes the effects of HFD, ovariectomy and DHEA on
body weight, insulin sensitivity, glucose tolerance, uterus weight, and
pancreatic islet area of rats. The ovariectomy induced up to 1.9-fold
increase in the body weight gain when compared to sham rats. Neither
the HFD nor DHEA treatment had an effect on changes in body weight
in the OVX and sham groups. OVX induced a 70% reduction in the
uterus weight when compared to the sham group, but uterus weight
was not altered by DHEA supplementation or HFD. The OVX group fed
a HFD had greater insulin resistance and associated hyperinsulinemia
compared to the sham groups, which was reversed by the treatment
with DHEA. Pancreatic islet area was greater in the OVX groups than
the sham groups, but was not altered by DHEA supplementation. 
The area under curve (AUC) of glucose tolerance test was not dif-
ferent between the groups ( P > 0.05). However analyses of the GTT
curve identiﬁed 2 time points with signiﬁcant differences, so that
15 min after glucose load the SHAM group showed lower glucose lev-
els when compared to SHL group ( P < 0.05). Furthermore, 60 min
after glucose load the OHL group showed higher glucose levels than
OVX group ( P < 0.05) ( Fig. 1 ). Static insulin secretion 
As expected, insulin secretion from the isolated pancreatic islets
of the SHAM group was 3-fold higher after incubation with 16.7 mM
glucose compared to 2.8 mM glucose ( Fig. 2 A and B). Ovariectomy or
exposure to the HFD alone had no effect on GSIS. In contrast, ovariec-
tomy combined with HFD impaired insulin secretion ( Fig. 2 B), which
was reversed with DHEA treatment. 
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Table 1 
DHEA, E2 (estradiol), P (progesterne), LH (luteinizing hormone), FSH (follicle stimulating hormone) and T (testosterone) concentrations of the SHAM, OVX (ovariectomized) and 
OVX + DHEA rats after 6 weeks ovarian removal. 
SHAM OVX OVX + DHEA P 
DHEA (pg / ml) 22.7 ± 2.1 a 26.3 ± 3.8 a 51.5 ± 3.2 b < 0.001 
E2 (pg / ml) 52.8 ± 4.1 a 28.4 ± 3.7 b 57.5 ± 6.9 a < 0.05 
P (ng / ml) 26.0 ± 5.8 a 9.5 ± 1.6 b 9.7 ± 2.4 b < 0.05 
LH (ng / ml) 9.6 ± 0.5 a 63.2 ± 8.0 b 54.5 ± 5.7 b < 0.01 
FSH (ng / ml) 4.8 ± 0.2 a 31.0 ± 3.7 b 27.1 ± 2.8 b < 0.05 
T (pg / ml) 94.8 ± 16.6 a 29.3 ± 3.4 b 27.6 ± 4.5 b < 0.05 
Values are mean ± S.E.M. n = 8–10. Groups with distinct letters means signiﬁcant difference ( P < 0.05). 
Table 2 
Changes in body weight and measures of insulin sensitivity in ovariectomized (OVX) or sham-operated (SHAM) rats treated with HFD and DHEA for 3 weeks. 
SHAM SHL OVX OHL OHLD 
 Body weight (g) 49 ± 8.4 a 67 ± 7.5 a 95 ± 8.4 b 102 ± 7.4 b 100 ± 6.7 b 
Weight uterus (g) 2.00 ± 0.30 a 1.70 ± 0.24 a 0.50 ± 0.03 b 0.50 ± 0.09 b 0.55 ± 0.05 b 
Insulin (ng / ml) 0.38 ± 0.06 ab 0.72 ± 0.13 ac 0.26 ± 0.04 b 0.92 ± 0.09 c 0.37 ± 0.03 b 
Glucose (mg / dl) 100 ± 3 a 119 ± 3 ab 103 ± 3 a 121 ± 4 b 108 ± 4 a 
AUC 20.94 ± 7.51 21.12 ± 9.56 20.2 ± 8.91 23.12 ± 5.17 22.2 ± 8.76 
Kitt (%min −1 ) 2.35 ± 0.20 a 2.28 ± 0.07 a 2.00 ± 0.14 a 1.00 ± 0.15 b 2.00 ± 0.14 a 
Islet area ( μm 2 ) 10.470 ± 825 a 13.270 ± 1.006 ab 15.260 ± 1.225 b 17.230 ± 1.500 b 17.630 ± 1.154 b 
Values are mean ± S.E.M. Similar letters indicate no signiﬁcant difference, while different letters indicate signiﬁcant difference ( P < 0.05).  Body weight (BW ﬁnal − initial); 
AUC: area under curve after 120 min of intraperitoneal glucose bolus; Kitt: glucose disappearance rate induced by 30 min Insulin Tolerance Test; SHL: sham rats fed a HFD; OVX: 
ovariectomized rats; OHL: ovariectomized rats fed HFD; OHLD: ovariectomized rats fed a HFD and treated with DHEA. n = 4–25. 
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pNA fragmentation 
The proportion of cells with DNA fragmentation was similar be- 
ween the OVX groups with values around 10% (data not shown). 
mmunoblotting analysis 
Fig. 3 A illustrates the protein expression of phosphoserine Akt 
p-Akt), and the protein expression of Akt, ERK1 / 2, caspase-3, using 
-tubulin as a control. Both HFD and OVX resulted in a 50% reduction 
n the phosphorylation state of Akt, with no additive effect of these 
wo conditions, which was reversed by DHEA treatment ( Fig. 3 B). 
here were no effects of HFD or OVX on protein expression of ERK1 / 2 
nd caspase-3 in the studied conditions ( Fig. 3 C and D). 
iscussion 
The levels of the sex steroid hormone DHEA decrease between the 
ges of 25 and 75 years, and has been related to body weight gain, 
besity and insulin resistance [ 33 ]. Conversely, studies have demon- 
trated that concentrations of DHEA and other sex steroid hormones 
re reduced with obesity and type 2 diabetes [ 34 ]. In addition, nu- 
erous studies using animal models have demonstrated that DHEA 
reatment increases insulin sensitivity [ 35 ] and GSIS [ 27 , 36 ]. 
In our study, despite the mild increase in body weight in OVX 
nimals, OVX in combination with a HFD (OHL rats) had no impact 
n body weight over the study period. However, the combination 
f OVX and HFD resulted in insulin resistance and impaired GSIS of 
he isolated pancreatic islets, which were reversed with DHEA sup- 
lementation. These ﬁndings reinforce the known effect of ovarian 
ormones on reducing the susceptibility of females to HFD-induced 
etabolic disturbance [ 37 ]. 
We suggest that DHEA treatment is involved in some aspects of 
athway-selective insulin resistance, which are independent of its 
ffects on body weight. This is supported by a study that showed 
hat a single DHEA injection in rats with streptozotocin-induced di- 
betes improves glucose metabolism-related signaling pathway via 
rotein kinase B (Akt) and reversed impaired GLUT-4-related signal- 
ng in muscle [ 38 ]. In our study OHL rats were the only group that 
resented with insulin resistance and functional beta cell damage, the latter probably caused by a defect in insulin signaling in β cells. 
Consistent with these reports, we showed that DHEA supplementa- 
tion, which increased estradiol levels, also increased the p-Akt / Akt 
ratio in pancreatic islets from OHLD animals, suggesting a possible 
role for Akt in normal glucose metabolism and β beta cell function in 
OHLD animals. Indeed, there is evidence showing that protein kinase 
Akt is important for the peripheral actions of insulin, such as glucose 
homeostasis, β cell growth and survival [ 39 ]. 
Studies also have suggested that Akt plays a important role in the 
regulation of distal components of the secretory pathway in the β
cell [ 40 ]. Transgenic mice with diminished Akt activity in their β cells 
present with glucose intolerance due to a defect in insulin secretion 
at the level of exocytosis process, which appears to be independent of 
the function of voltage-gated Ca2 + channels [ 40 ]. Furthermore, acute 
inhibition of PI3K-PDK1-Akt pathway increased GSIS by upregulation 
of speciﬁc intracellular fusion events from newcomer granules [ 41 ]. 
On the other hand, inhibition of class IA phosphatidylinositol 3-kinase 
(PI3K) also resulted in glucose intolerance and reduced GSIS [ 42 ]. 
In the present study, extracellular signal-regulated protein ki- 
nases 1 and 2, ERK1 / 2, which is involved on cellular proliferation, 
growth, and differentiation, were not altered by HFD, ovariectomy or 
DHEA treatment. Similarly, pathways related to cell death were not 
involved, since no changes in DNA fragmentation and cleaved caspase 
3 expressions were observed in any of the treatment groups. 
In summary, our study showed that OVX in combination with 
a HFD resulted in a signiﬁcant increase in body weight, as well as a 
reduction in insulin sensitivity and secretion. Independent of changes 
in body weight, the changes in insulin sensitivity and secretion were 
normalized after 3 weeks of the DHEA pellet insertion. This effect 
was mediated by an increase in the p-Akt / Akt ratio. These ﬁndings, 
in addition to the higher prevalence of insulin resistance and type 2 
diabetes in women after menopause, provide support for a potential 
therapeutic role of DHEA in post-menopausal women that have some 
features of the metabolic syndrome. 
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Fig. 3. Protein levels of Akt, ERK1 / 2, and cleaved caspase 3 of isolated pancreatic islets in SHAM, SHL, OVX, OHL and OHLD groups. Panel A is the immunobloting of pAkt, Akt, 
ERK1 / 2, cleaved caspase 3 and α-tubulin. Panel B is the stoichiometric relationship between the serine phosphorylation status of Akt (p-Akt) and the protein expression of Akt 
(pAkt / Akt). Panel C is the protein level of ERK1 / 2. Panel D is the protein level of cleaved caspase-3. The values are expressed as the mean ± S.E.M. and distinct letters indicate 
signiﬁcance ( P < 0.05). 
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